Video

Dr. Kuerer on Eliminating Breast Cancer Surgery

Henry M. Kuerer, MD, PhD, professor of Surgery, The University of Texas MD Anderson Cancer Center, discusses the elimination of breast cancer surgery in exceptional responders.

Henry M. Kuerer, MD, PhD, professor of Surgery, The University of Texas MD Anderson Cancer Center, discusses the elimination of breast cancer surgery in exceptional responders.

In a recent study by the MD Anderson Cancer Center, the feasibility of eliminating surgery in patients with triple-negative and HER2-amplified breast cancers was assessed. These were patients who exhibited an exceptional response rate after being treated with neoadjuvant chemotherapy which, routinely, has a complete eradication of disease in up to 60% of patients in the breast and lymph nodes.

With imaging still being an ineffective tool to help predict response, biopsy with imaging is being looked at to identify patients that may be eligible to bypass surgery.

In the combination of standard radiotherapy with image-guided, extensive vacuum-assisted core biopsy, following neoadjuvant therapy, the trial met its endpoint with accuracy at nearly 98%, with a false negative rate of 5%, and a negative predictive value of about 95%.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity